American Psychiatric Association

CCC to Issue Updates to Market Report on Scholarly Metadata at the Society for Scholarly Publishing Annual Meeting

Retrieved on: 
Jeudi, mai 23, 2024
Research, Legal, Technology, Publishing, Communications, Professional Services, Software, Science, Artificial Intelligence, Other Science, Society for Scholarly Publishing, Machine, Information, Regeneron Pharmaceuticals, DEI, SSP, Initiative, Metadata, London Book Fair, American Psychiatric Association, EDT, Information services, Intelligence, Society, AI, Growth, Open access, Automation, Implement, Knowledge, CCC, Medical device

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that the newest edition of The State of Scholarly Metadata report, which depicts the complexities and value of scholarly publishing metadata, will be made available at the 2024 Society for Scholarly Publishing (SSP) 46th Annual Meeting 29-31 May at the Westin Boston Seaport District .

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that the newest edition of The State of Scholarly Metadata report, which depicts the complexities and value of scholarly publishing metadata, will be made available at the 2024 Society for Scholarly Publishing (SSP) 46th Annual Meeting 29-31 May at the Westin Boston Seaport District .
  • Based on direct input from the community, the report now showcases important initiatives working to improve metadata management.
  • The report will be available online via the CCC website .
  • They will lead the audience in creating a GenAI prompt to give SSP guidance on the future of scholarly publishing.

Teens Ages 15 to 19 Incur Highest Mental Health Spending for Depression, Anxiety, and Autism Diagnoses, Analysis Reveals

Retrieved on: 
Mardi, mai 21, 2024
Health Technology, Health Insurance, Data Management, Other Health, Technology, General Health, Professional Services, Mental Health, Teens, Science, Payments, Software, Consumer, Data Analytics, Research, Health, Patient, American Psychiatric Association, Employment, Organization, Education, Anxiety, Mental health, Database, DSM-IV codes, MD, Mental Health Awareness Month, Disability, Nursing

Behavioral and mental health is also the highest category for healthcare spending overall among children ages 5 to 19.

Key Points: 
  • Behavioral and mental health is also the highest category for healthcare spending overall among children ages 5 to 19.
  • “ Studies confirm that investing in mental health care yields significant savings in future healthcare costs and criminal and juvenile justice costs and improves workplace productivity.
  • Millions of people experience the first signs of behavioral and mental health disorders as teens or young adults.
  • According to the American Psychiatry Association, nearly one in five (19%) U.S. adults experience some form of mental illness.

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Retrieved on: 
Mardi, mai 14, 2024
Patient, ALKS, Pharmacoeconomics, Health, Bipolar I disorder, ARISTADA, APA, American Psychiatric Association, International Society, Safety, Mental Health Awareness Month, Efficacy, Research, Psychiatry, Olanzapine, Schizophrenia, ASCP, Annual general meeting, Pharmaceutical industry

DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings include:

Key Points: 
  • DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring.
  • "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of evidence for our medicines and advancing understanding of their real-world impact.
  • Highlights of the upcoming presentations include:
    Findings from an international, multicenter, phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment.
  • Results from a real-world study of treatment patterns and healthcare resource utilization among patients with schizophrenia before and after initiating ARISTADA using the ARISTADA INITIO® initiation regimen.

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Retrieved on: 
Mardi, mai 14, 2024
Patient, ALKS, Pharmacoeconomics, Health, Bipolar I disorder, ARISTADA, APA, American Psychiatric Association, International Society, Safety, Mental Health Awareness Month, Efficacy, Research, Psychiatry, Olanzapine, Schizophrenia, ASCP, Annual general meeting, Pharmaceutical industry

DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings include:

Key Points: 
  • DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring.
  • "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of evidence for our medicines and advancing understanding of their real-world impact.
  • Highlights of the upcoming presentations include:
    Findings from an international, multicenter, phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment.
  • Results from a real-world study of treatment patterns and healthcare resource utilization among patients with schizophrenia before and after initiating ARISTADA using the ARISTADA INITIO® initiation regimen.

Marking 75 Years of Mental Health Advocacy: Leaders meet on Capitol Hill to Amplify Voices and Foster Compassion

Retrieved on: 
Lundi, mai 13, 2024
Mental health, Hope, NFL, American Psychiatric Association, Health, LDH, AVP, Mental Health Awareness Month, Assistant, Former, OBH, Public policy, Government, Family, CDC, Nursing

However, despite 75 years of awareness efforts, openly discussing mental health remains challenging in our country.

Key Points: 
  • However, despite 75 years of awareness efforts, openly discussing mental health remains challenging in our country.
  • On May 15th, mental health leaders will gather in our nation's capital to host a groundbreaking briefing.
  • On Wednesday, May 15th, national mental health organizations, leaders, and advocates will gather in our nation's capital to host a groundbreaking briefing featuring speakers and panelists.
  • These conversations seek to increase awareness through personal stories and firsthand experiences while shedding light on critical issues in mental health across our nation.

Defined Sleep to Share Groundbreaking Research at the American Psychiatric Association 2024 Conference

Retrieved on: 
Mardi, mai 7, 2024
Research, General Health, Cannabis, Pharmaceutical, Mental Health, Natural Resources, Hemp, Clinical Trials, Science, Alternative Medicine, Other Science, Health, APA, Sleep hygiene, CBD, Therapy, Annual general meeting, Interview, Mental health, American Psychiatric Association, Psychiatry, Sleep, Lead, Nursing

Defined Sleep, a pioneer in scientifically developed, supported, and validated CBD sleep supplements , is proud to announce its upcoming participation in the American Psychiatric Association (APA) 2024 Annual Meeting from May 4-8, 2024.

Key Points: 
  • Defined Sleep, a pioneer in scientifically developed, supported, and validated CBD sleep supplements , is proud to announce its upcoming participation in the American Psychiatric Association (APA) 2024 Annual Meeting from May 4-8, 2024.
  • At the conference, Defined Sleep will showcase its latest research findings at their exhibition booth on the critical link between sleep quality and mental health.
  • The Defined Sleep research team, led by Dr. Paul Muchowski, will highlight evidence-based strategies for enhancing sleep hygiene to improve overall mental well-being.
  • Expertise in Science: The founder of Defined Sleep will share information about practical sleep hygiene techniques for mental health professionals.

Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement

Retrieved on: 
Lundi, mai 6, 2024
Mental Health, Health, FDA, Technology, Other Technology, Mobile, Wireless, General Health, APA, Ōtsuka, Nephrology, American Psychiatric Association, Food, OAI, Artificial intelligence, Therapy, DSM-IV codes, Mental health, Patient, OPH, Annual general meeting, Food and Drug Administration, MDD, Pharmaceutical industry

OPH will focus on the patient experience as a core piece of improving how better outcomes might be achieved across nephrology, mental health, and beyond.

Key Points: 
  • OPH will focus on the patient experience as a core piece of improving how better outcomes might be achieved across nephrology, mental health, and beyond.
  • OPH will serve to commercialize Rejoyn™.
  • Otsuka is deepening its commitment to the meaningful role technology can play in the lives of patients and the care teams that surround them.
  • “At this time there is a great desire for alternative therapies and treatments in the mental health space, especially given the outpaced demand in recent years,” said Shah.

The Inner Circle Acknowledges Katherine A. Daly, MD, as a Distinguished Medical Professional

Retrieved on: 
Jeudi, mai 2, 2024
American Academy, University, Adolescence, Differential diagnosis, American Psychiatric Association, Psychiatry, Woman, Dream, Heart, M Health Fairview, American Medical Association, Love, MD, Bentham Science Publishers, Epilepsy, Panic disorder, Trinity Health (Livonia, Michigan), Physician, Inner circle, Nursing

WAYZATA, Minn., May 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Katherine A. Daly, MD, is acknowledged as a Distinguished Medical Professional for her work in the Pediatrics and Psychiatry Fields.

Key Points: 
  • WAYZATA, Minn., May 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Katherine A. Daly, MD, is acknowledged as a Distinguished Medical Professional for her work in the Pediatrics and Psychiatry Fields.
  • Dr. Daly began her academic journey at the University of Minnesota Medical School where she earned a Medical Doctor (M.D.)
  • She then completed an internship in 1993 with Loyola Medicine MacNeal Hospital and finished residencies in pediatrics in 1996 and psychiatry in 1998.
  • The doctor capped her scholarship with a fellowship training in child and adolescent psychiatry in 2000 at the University of Minnesota Medical School.

Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research

Retrieved on: 
Jeudi, mai 2, 2024
Software, Practice Management, General Health, Health, Mental Health, Data Management, Health Technology, Technology, APA, Education, RWE, American Psychiatric Association, Psychiatry, Private practice, EHR, MD, Collection, Automation, Patient, MBC, Medicine, Nursing

Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.

Key Points: 
  • Today, Osmind , the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry.
  • This collaboration between Osmind and APA’s PsychPRO registry intends to broaden access to personalized care, improve patient outcomes, generate robust real-world evidence (RWE) and accelerate psychiatry’s evolution to precision medicine.
  • PsychPRO registry is a clinical data registry that enables the collection and analysis of clinical data to advance quality improvement efforts and accelerate research for the psychiatric community.
  • Through this collaboration, Osmind is enabling independent practices to contribute to the evolution of the field and elevate their own evidence-based practices.

MindMed to Present at Upcoming May Medical Conferences

Retrieved on: 
Jeudi, avril 25, 2024
Mental Health, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, APA, Congress, American Psychiatric Association, MindMed, Epidemiology, Medicine, GAD, Pharmacoeconomics, Lysergic acid diethylamide

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
    American Psychiatric Association (APA) 2024 Congress, New York, NY
    Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
    Posters will be available on MindMed’s Company website following the conferences.